BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28782639)

  • 1. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
    Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
    Piao ZH; Zhou XC; Chen JY
    Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].
    Lao I; Chen Q; Yu L; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):364-9. PubMed ID: 25208984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
    Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
    Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases.
    Pavlisko EN; Roggli VL
    Am J Surg Pathol; 2015 Nov; 39(11):1568-75. PubMed ID: 26371785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and pathologic features of extrapleural sarcomatoid mesothelioma].
    Wei MC; Yang SJ
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):559-564. PubMed ID: 28810297
    [No Abstract]   [Full Text] [Related]  

  • 9. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
    Berg KB; Churg A
    Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
    Cagle PT; Truong LD; Roggli VL; Greenberg SD
    Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcomatoid neoplasms of the lung and pleura.
    Travis WD
    Arch Pathol Lab Med; 2010 Nov; 134(11):1645-58. PubMed ID: 21043818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
    Klebe S; Swalling A; Jonavicius L; Henderson DW
    J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
    Attanoos RL; Thomas DH; Gibbs AR
    Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
    Klebe S; Mahar A; Henderson DW; Roggli VL
    Mod Pathol; 2008 Sep; 21(9):1084-94. PubMed ID: 18587319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of pleural epithelioid sarcoma of proximal type presenting as malignant pleural mesothelioma.
    Madsen GA; Rasmussen TR; Bærentzen S
    J Thorac Oncol; 2013 Oct; 8(10):e89-90. PubMed ID: 24457248
    [No Abstract]   [Full Text] [Related]  

  • 20. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.